Table 1. Comparison of cell viability under Cap treatment in three different glioma cell lines.
| MTT Assay Post-Treatment (hours) | Duration of CAP Treatment (seconds) | Glioma Cell Line % Viability (SEM) | ||
|---|---|---|---|---|
| A172, (n = 22) | U373, (n = 22) | U87 (n = 22) | ||
| 24 | 60 | 86 (0.09) | 97 (0.04) | 90 (0.05)* |
| 90 | 69 (0.03)* | 64 (0.06)* | 76 (0.04)* | |
| 120 | 17 (0.04)* | 28 (0.07)* | 32 (0.09)* | |
| 180 | 4 (0.04)* | 6 (0.01)* | 7 (0.01)* | |
| 48 | 60 | 88 (0.2) | 67 (0.05)* | 81 (0.04)* |
| 90 | 45 (0.1)* | 42 (0.06)* | 56 (0.04)* | |
| 120 | 14 (0.03)* | 28 (0.08)* | 31 (0.03)* | |
| 180 | 13 (0.04)* | 28 (0.09)* | 7 (0.02)* | |
| 72 | 60 | 114 (0.14) | 59 (0.05)* | 74 (0.04)* |
| 90 | 33 (0.04)* | 31 (0.06)* | 55 (0.02)* | |
| 120 | 9 (0.02)* | 18 (0.05)* | 13 (0.03)* | |
| 180 | 12 (0.05)* | 10 (0.03)* | 6 (0.02)* | |
Results of MTT assay from three glioma cell lines, A172, U373, and U87 treated with varying durations of cold atmospheric plasma (CAP). After treatment, the MTT assay was performed at 24, 48, and 72 hours. Viability was calculated relative to control.
*Denotes significance to p< 0.05 relative to control.